(Adnkronos) - Il Centro nazionale di ricerca su terapia genica e farmaci RNA, uno dei cinque centri nazionali finanziati nell’ambito del programma NextGeneration EU, ha organizzato oggi a Milano un incontro nel corso del quale si è tracciato un bilancio dei progetti portati avanti sino ad oggi, illustrando le possibili sfide per il futuro, tra cui un maggiore coinvolgimento degli investitori privati nelle attività di ricerca. Un incontro utile per far emergere il valore della rete di ricerca organizzata e gestita dal Centro coinvolgendo 25 università, 7 atenei privati e fondazioni e 14 aziende per un totale di circa 1300 scienziati che lavorano quotidianamente per individuare e realizzare nuovi farmaci basati sulla tecnologia a RNA, utili per la cura e il trattamento di malattie genetiche, cancro, patologie metaboliche e cardiovascolari, disturbi neurodegenerativi, malattie infiammatorie e infettive.
Category
🗞
NewsTranscript
00:00Italian research is at a very high level in some of the most advanced sectors of world medicine,
00:10with the aim of making available as soon as possible innovative, precise and sustainable cures for a wide range of pathologies,
00:17often incurable, in the field of genetics, oncology, metabolic and cardiovascular, neurodegenerative, inflammatory and infectious.
00:25This is the essence of the National Research Center for the Development of Genetic Therapy and Pharmaceuticals with RNA Technology since 2022,
00:33year of its foundation, and that during the press conference on Genetic Therapy and RNA,
00:38the challenge of Italian research for a personalized and sustainable medicine,
00:42has illustrated the results of the first two years of studies funded by the PNRR,
00:47and now aims to attract new private investments to enhance the work of more than 1,500 Italian scientists and researchers.
00:55A great commitment to eradicate in Italy an emerging technology of the care of citizens,
01:05that is to fully exploit RNA, an extraordinary molecule that allows to act on any target within the cell.
01:15Genetic therapy, therefore the possibility of correcting defects or introducing new tools of care,
01:22so that new categories of drugs can be produced that are able to actually act on personalized medicine,
01:30that is, medicine that is able to identify the difference between patient and patient,
01:36and produce for each patient the most targeted drug,
01:40and therefore that will be more effective and with less side effects for the cure of diseases.
01:45The SPOC10, coordinated by the President of the Superior Council of Health, Franco Locatelli,
01:50focuses on the approaches of genetic therapy for the cure of hereditary diseases,
01:54the treatment of neoplasia or autoimmune diseases.
01:58Thanks to the funding received in the country,
02:01experiments have already been launched for the treatment of an acute leukemia variant,
02:10acute lymphoblastic leukemia of type T and neoplasia of the central nervous system,
02:17through a phase 1-2 protocol that puts our country at the forefront in the European context.
02:28Over the past few years, a zoo of different RNA molecules has been discovered,
02:33and now they are working to modify them and turn them into drugs.
02:37Drugs that can be both yin and yang,
02:41that is, they can be inhibitors of the genetic expression of a pharmacological target,
02:47or activators, and therefore we can inhibit the expression of some genes that are toxic,
02:54or increase others that are neuroprotective.
02:57Today we have understood, we have reasoned about how this is part of a wider spectrum plan,
03:06in such a way that Italy, on these issues, is at the forefront of the world,
03:12in such a way as to be able to take advantage of the excellent research that is taking place in our country
03:18and promote technological transformation in the construction of new drugs.